Join
Live feed
·
PRReleasevia Quantisnow
TransCode Therapeutics Inc. logo

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

ByQuantisnow·Wall Street's wire, on your screen.
RNAZ· TransCode Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNAZ (TransCode Therapeutics Inc.) and more on Quantisnow.